This report gives a list of companies dealing with this problem. My simple conclusion is that ATH should make an agreement with all these companies and even many more corresponding companies to get what PBT2 is offering to ALT.
- Pfizer Inc
- GlaxoSmithKline plc
- Merck & Co., Inc.
- Johnsons & Johnson
- Baxter Healthcare Corporation
- Zydus Cadila
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- Reddy’s Laboratories Ltd.
- Mayne Pharma Group Limited.
- Sun Pharmaceutical Industries Ltd.
- Cipla Inc.
- Shanghai Pharmaceutical Group Co., Ltd.
- Yuhan Corporation
- Abbott Laboratories
This report gives a list of companies dealing with this problem....
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $26.22M | |||
| Open | High | Low | Value | Volume |
| 0.5¢ | 0.6¢ | 0.5¢ | $3.342K | 666.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 37 | 32719984 | 0.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.6¢ | 15288198 | 22 |
View Market Depth
| Last trade - 14.04pm 29/05/2024 (20 minute delay) ? |
|
|||||
|
Last
0.6¢ |
Change
0.000 ( 10.0 %) |
||||
| Open | High | Low | Volume | ||
| 0.5¢ | 0.6¢ | 0.5¢ | 140816 | ||
| Last updated 11.48am 29/05/2024 ? | |||||
| ATH (ASX) Chart |